Atlas Venture Fund XI L.P. 13D and 13G filings for Dyne Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:32 pm Sale | 2024-09-30 | 13G | Dyne Therapeutics, Inc. DYN | Atlas Venture Fund XI L.P. | 5,714,057 5.700% | -1,628,026 (-22.17%) | Filing |
| 2024-02-09 4:09 pm Purchase | 2023-12-31 | 13G | Dyne Therapeutics, Inc. DYN | Atlas Venture Fund XI L.P. | 7,342,083 9.100% | 15,966 (+0.22%) | Filing |
| 2023-02-14 4:29 pm Unchanged | 2022-12-31 | 13G | Dyne Therapeutics, Inc. DYN | Atlas Venture Fund XI L.P. | 7,326,117 14.100% | 0 (Unchanged) | Filing |
| 2022-02-11 5:04 pm Sale | 2021-12-31 | 13G | Dyne Therapeutics, Inc. DYN | Atlas Venture Fund XI L.P. | 7,326,117 14.200% | -814,013 (-10.00%) | Filing |
| 2021-02-16 5:28 pm Purchase | 2020-12-31 | 13G | Dyne Therapeutics, Inc. DYN | Atlas Venture Fund XI L.P. | 8,140,130 17.900% | 8,140,130 (New Position) | Filing |